Please assess the completion status of the following clinical trial:

Trial Title: Study of Safety and Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes And Hypertension (MK-8835-042)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with type 2 diabetes and hypertension~* Medically stable~* On at least 1 (and up to 2) oral diabetes drugs~* And up to 2 medicines for blood pressure control~Exclusion Criteria:~* Participants with type 1 diabetes~* Heart attack~* Stroke~* Uncontrolled blood pressure~* Significant kidney disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo to ertugliflozin (resembling either 1 mg or 5 mg), placebo to ertugliflozin (resembling 25 mg), and placebo to HCTZ once daily for 28 days.
- Ertugliflozin 1 mg (Type: EXPERIMENTAL): Ertugliflozin 1 mg, placebo to ertugliflozin (resembling 25 mg), and placebo to HCTZ once daily for 28 days
- Ertugliflozin 5 mg (Type: EXPERIMENTAL): Ertugliflozin 5 mg, placebo to ertugliflozin (resembling 25 mg), and placebo to HCTZ once daily for 28 days
- Ertugliflozin 25 mg (Type: EXPERIMENTAL): Ertugliflozin 25 mg, placebo to ertugliflozin (resembling either 1 mg or 5 mg), and placebo to HCTZ once daily for 28 days
- HCTZ 12.5mg (Type: ACTIVE_COMPARATOR): HCTZ 12.5 mg, placebo to ertugliflozin (resembling either 1 mg or 5 mg), and placebo to ertugliflozin (resembling 25 mg) once daily for 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).